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Abstract Expression of the serotonin transporter is
affected by the genotype of the 5-HTTLPR (short and long
forms) as well as the genotype of the SNP rs25531 within
this region. Based on the combined genotypes for these
polymorphisms, we designated each allele as a high or low
expressing allele according to established expression lev-
els—resulting in HiHi, HiLo, & LoLo genotype groups for
analysis. We evaluated effects of gender and the promoter
genotype on induction of negative affect by intravenous
infusion of L-tryptophan (TRP). The protocol consisted of a
day-1 sham saline infusion and a day-2 active TRP infu-
sion. Models assessed 5-HTTLPR composite genotype and
gender as predictors of change in ratings of negative
emotion during TRP infusion. During sham infusion there
were no significant changes from baseline in mood ratings.
During TRP infusion all negative affect ratings increased
significantly from baseline (P’s \ .02). The geno-
type 9 gender interaction was a significant predictor of
depression-dejection (P = .013), and trended towards
predicting anger-hostility (P = .084). Males in the HiHi
group had greater increases in negative affect during
infusion, compared to all groups except LoLo females, who
also showed increased negative affect.
Keywords 5-HTTLPR  Gender  L-tryptophan 
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Introduction
An extensive literature, using increased blood prolactin
levels as an index of central nervous system (CNS) sero-
tonin function, documents that intravenous infusion of the
serotonin precursor L-tryptophan (TRP) increases central
serotonin (5-HT) function (Checkley 1980; Price et al.
1990; Yatham and Steiner 1993). The theory that individ-
ual differences in CNS 5-HT function account for
differences in disposition has been widely examined using
neuroendocrine challenge protocols that alter CNS seroto-
nin activity (e.g., intravenous infusion of TRP and oral
fenfluramine). Challenge studies have demonstrated asso-
ciations among emotionally related behavioral traits and
central serotonergic activity (e.g., Cleare and Bond 1995;
Cleare and Bond 1997; Coccaro 1992; Coccaro et al. 1989;
Marsh et al. 2002; Moeller et al. 1994; O’Keane et al.
1992). Findings from challenge protocols that enhance
CNS 5-HT neurotransmission have also documented that
gender differences exist with respect to associations among
serotonergic activity and personality traits. For example,
neuroticism has been negatively related to prolactin
response to a fenfluramine challenge, but only for males
(Manuck et al. 1998). In addition to demonstrations of
associations among personality traits and CNS serotonin
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function, transient changes in mood have been assessed
during serotonin enhancement protocols. Assessments of
mood during TRP infusion in healthy samples has gener-
ally shown worsening of affect, and/or increased feelings
related to lack of energy (Cowen and Charig 1987; Hen-
inger et al. 1984; Price et al. 1991).
A related body of literature indicates that the serotonin
system in men and women may behave quite differently in
important ways. One study using positron emission
tomography has shown that in males the rates of central
nervous system (CNS) serotonin synthesis are approxi-
mately 50% higher than in females (Nishizawa et al. 1997).
Conversely two studies using a different index of CNS
5-HT have shown that cerebrospinal fluid (CSF) levels of the
major serotonin metabolite 5 HIAA are higher in women
than in men (Jonsson et al. 2000; Williams et al. 2003).
Moreover, 5 HT1A and 5 HT2 receptor density is lower in the
brains of women than men (Biver et al. 1996; Costes et al.
2005) and selective serotonin re-uptake inhibitors (SSRI)
have greater efficacy in women, as compared to men
(Kornstein et al. 2000). As previously noted, individual dif-
ferences in CNS 5-HT function are thought to account for
differences in disposition and research findings in this area
also suggests that the serotonin transporter gene promoter
polymorphism (5-HTTLPR) genotype may have an opposite
effect on behavioral characteristics in men and women. In
some studies, the presence of the L allele has been associated
with higher levels of depressive symptoms and/or negative
affect in males, whereas, in females it is those carrying the S
allele who exhibit such symptoms (Brummett et al. 2008,
2003; Eley et al. 2004; Flory et al. 1999; Gonda et al. 2005;
Jacobs et al. 2006; Sjoberg et al. 2006; Surtees et al. 2006).
However, some findings in related constructs are in the
opposite direction. Specifically, higher levels of neuroticism
(Du et al. 2000) and harm avoidance (Gelernter et al. 1998)
have been associated with the s allele, but in males only. One
potential confounder to some of these results is that the
activity of the short (S) and long (L) alleles of the 5-HTTLPR
has been shown to be modified by a single nucleotide poly-
morphism (SNP) within the region (rs25531) (Hu et al.
2006), which has not frequently been analyzed in the past.
Thus, the topic of gender and genotype on negative effects
clearly merits further investigation including more careful
examination with respect to the categorization of serotonin
transporter alleles.
In the present study we analyzed negative affective
responses assessed during a TRP enhancement challenge
that consisted of a day-1 sham saline infusion and a day-2
active TRP infusion. Building on the above research that
indicates allelic variation in 5-HTTLPR may have an
opposite effect on behavioral characteristics in men and
women and that results of challenge protocols have shown
gender differences in associations among CNS serotonergic
activity and mood, we included examination of gender and
genetic variation in the serotonin polymorphism 5-HTTLPR
as predictors of emotional responding to a TRP challenge.
We included examination of the A/G SNP (rs25531) that
modifies the activity of the insertion/deletion polymorphism,
resulting in a multiallelic marker for which the most common
alleles are LG, LA, and S (Hu et al. 2006). Previously, LG and
S alleles were shown to be associated with comparably lower
transcriptional activity relative to the LA allele (Hu et al.
2006). Therefore, for our analyses composite alleles were
categorized according to transcriptional activity (LA as Hi,
and LG & S as Lo); resulting in 3 genotype groups (HiHi,
HiLo, & LoLo). Regression models were used to assess these
5-HTTLPR genotype groups and gender as moderators of




Participants were invited to take part in a study designed to
examine the moderating effects of genetic, behavioral, and
environmental mechanisms on health disparities. Recruit-
ment took place from 1998 to 2003 and consisted of
advertisements in the public media, inclusion in the com-
munity newsletter sent with the county water bill, flyers
posted throughout the community, outreach screening
events at civic organizations and other public events, and
paid advertisements such as the back of supermarket tapes.
The study was conducted at Duke University Medical
Center and all subjects gave informed consent prior to their
participation in the study using a form approved by the
Duke University Medical Center Institutional Review
Board. Those enrolled in the study received $500 for their
participation. The study protocol required that participants
be in good current health because of the study procedures,
(see below) (Williams et al. 2001, 2003) and; therefore, all
participants underwent a comprehensive psychological
examination, as well as medical history, physical exam,
electrocardiogram, chest radiograph, hemoglobin, hemat-
ocrit, white cell count, and blood chemistries to rule out
current medical and psychiatric disorders (including
depression). Use of any prescription drugs as well as use of
illegal drugs (as detected by a urine screen prior to entry
into study) were grounds for exclusion (Burroughs et al.
2003). The study sample consisted of 80 participants and it
was later found that 1 participant did not meet inclusion
criteria. Of the remaining 79 individuals, 7 did not have
data for genotype or affect assessment during the protocol,
resulting in 72 participants (31 females and 41 males) who
are the focus of the present study.
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Procedure
Upon evening admission to the Clinical Research Unit at
Duke University Medical Center, sociodemographic and
personality data were gathered, and blood was drawn for
assessment of biological parameters. Test day one con-
sisted of a sham TRP infusion using saline (see Williams
et al. 2001), and test day two consisted of an active TRP
infusion. With the exception of administration of either the
active or sham TRP infusion, the protocol for days 1 and 2
were identical.
Tryptophan challenge protocol
On the day of the active TRP infusion, beginning at
6:30 a.m. participants were not allowed food or liquids, nor
were they allowed to smoke, until the completion of all study
procedures at approximately 1:30 p.m. At 7:00 a.m. an IV
(D5W/0.5 N saline) was started and kept running at 50 cc
per hour till 1:30 p.m. All participants were seated in a
reclined position and activity was limited to watching nature
videos provided by the investigator or playing cards. Bath-
room visits were allowed up to the time of tryptophan
infusion. At 11:00 a.m. participants received either a full
dose of TRP (100 mg/kg body weight) or saline over a period
lasting 25 min. A blood pressure cuff was placed around the
infusion bag and inflated up to a maximum of 35 mmHg if
needed to complete the total dose within 25 min. At the end
of the infusion, the IV was returned to D5W/0.5 N saline.
The challenge protocol was carried out under single-blind
conditions, with participants unaware of condition.
Affect assessment
Negative emotional states were assessed using the Profile
of Mood States (POMS) (McNair and Lorr 1964). Affect
was assessed prior to infusion (baseline) and again 1 hour
post the start of infusion, for both sham and active days.
The POMS consists of affective items (rated 0 = not at all
to 4 = extremely) which may be summarized, creating 4
scales that represent the negative affect dimensions of:
anger-hostility, depression-dejection, fatigue-inertia,
and tension-anxiety. The POMS has been frequently used
to examine mood change during challenge studies (Richell
et al. 2005; Van der Does 2001), and has acceptable
validity and reliability (Knapp et al. 1998).
Genotyping
The promoter region surrounding the 5-HTTLPR and
rs25531 polymorphisms was amplified and used to create a
composite genotype reflecting the alleles of both poly-
morphisms. PCR of the promoter region was performed in
a 25-ll volume with 30 ng DNA, 19 PCR Buffer (Invit-
rogen 109 PCR Buffer); 1.5 mM MgCl2 (Invitrogen
50 mM MgCl2); 0.2 mM each of dATP, dCTP, and dTTP;
0.1 mM dGTP; 0.1 mM 7-deaza dGTP; 4 ng/ll of each
primer; 0.03 U/ll Platinum Taq DNA polymerase; and
7.5% DMSO. The forward primer was 50FAM-
GGCGTTGCCGCTCTGAATGC-30, and the reverse pri-
mer was 50-AGGGACTGAGCTGGACAACCAC-30. The
DNA was denatured at 95C for 5 min. For 37 cycles, the
DNA was denatured at 95C for 30 s, annealed at 61C for
30 s, and extended at 72C for 1 min. PCR was terminated
by an extension at 72C for 5 min. The PCR product was
purified by adding 5 ll of SOPE resin (Edge Biosystems)
to the product and eluting the mixture through a sephadex
column. 1 ll of the purified PCR product was diluted in
24 ll of dH20 for 5-HTTLPR genotyping. The rest of the
purified product was kept for genotyping the SNP
(rs25531) within the insertion/deletion.
The 5-HTTLPR marker was genotyped by size separation
of the PCR fragment on the 3730 DNA Analyzer (Applied
Biosystems). The PCR products were sized utilizing the
1200LIZ size standard (Applied Biosystems) which captures
the rare extra long (XL) allele as well as the standard long (L)
and short (S) alleles associated with this marker. The raw
data was examined in GeneMapper (Applied Biosystems) to
determine the alleles for each sample.
The rs25531 marker was genotyped by digesting the
PCR product with HpaII, a restriction enzyme that cuts at
the SNP site only if the G allele is present. The digestion
was cleaned with sephadex and the fragments were size
separated on a 3730 DNA Analyzer using the 500LIZ Size
Standard (Applied Biosystems). Of the resulting fragments
from the digestion, only those from the FAM labeled end of
the PCR product can be detected on the 3730. The raw data
was examined in GeneMapper to determine the alleles for
each sample. The LA allele peak was detected at 332 bp;
the LG allele peak was detected at 162 bp; and the SA allele
peak was detected at 289 bp. Theoretically, if a Sg were
present it would also be detected as it would present as a
short allele in the 5-HTTLPR size separation, but run with
the Lg in the rs25531 genotyping. However, we did not
identify any Sg alleles, suggesting these alleles are rare.
Therefore, genotypes designated S are technically SA. Size
estimation from Genemapper is not exact. However, these
sizes were consistent with the theoretical fragment sizes
calculated using HpaII to digest the PCR product.
The resulting genotypes from both procedures were used
to create a composite genotype reflecting S, La, Lg, and XL
alleles. These genotypes were then categorized as high or
low expressing based on previous literature. The XL alleles
were categorized with the LA as Hi expressing.
Additional quality control for all genotyping consisted
of duplicate DNA’s placed throughout the DNA plates in
478 Behav Genet (2008) 38:476–483
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which 100% matching results were required. Laboratory
technicians were blinded to the matching pattern of these
duplicates. We also required greater than 95% efficiency on
each genotyping protocol, i.e., no more than 5% of the
samples processed could fail the assay.
This modified genotyping approach has several advanta-
ges over previous genotyping protocols for these
polymorphisms. While many protocols have used this primer
set to obtain the 5-HTTLPR polymorphism, the current
approach utilizes the same PCR product for genotyping the
rs25531 polymorphism. Consequently, the presence of
additional HpaII sites in the PCR product allow for differ-
entiation between heterozygosity of rs25531 and partial
digestion. This provides reliable high-throughput genotyp-
ing without need for exact quantification of PCR product
prior to digestion. Additionally, use of a capillary sequencer
for size separation also increased throughput and automation
over running the digest on agarose gels. By utilizing the dual
genotyping methods, we were able to identify the XL alleles
that were previously difficult to identify after digestion, to
verify that no Sg alleles were present, as well as to provide
some additional quality control for determining alleles, as
the calls for short or long alleles must be consistent between
the two genotyping methods.
Analysis
For sham and active infusion days, change scores were
created for the 4 negative affect dimensions by subtracting
the pre-infusion (baseline) rating from the post-infusion
rating for each affect dimension. Paired t-tests were con-
ducted on these change scores to assess whether or not
affect ratings changed significantly from pre-TRP to post-
TRP infusion. In linear regression models, gender and
5-HTTLPR were used to predict change in the affect
summary scores for anger-hostility, depression-dejec-
tion, fatigue-inertia, and tension-anxiety. Regression
models were adjusted for baseline affect and race. Each
initial model included a term representing gender, geno-
type (HiHi, HiLo, or LoLo transcriptional activity), race
(Caucasian or African American), and the baseline affect
rating; along with a gender 9 genotype interaction term
allowing us to examine moderation by these two factors.
Nonsignificant interaction terms were then removed prior
to final examination of main effects.
Results
Demographic characteristics
With respect to ethnicity, 39 (54.2%) of the participants
were African American and the remaining 33 (45.8%) were
Caucasian. The average participant was 33.5 (S.D, 9.1)
years old. Genotype classification of transcriptional activity
was distributed as follows: HiHi = 26 (36.1%);
HiLo = 30 (41.7%); LoLo = 16 (22.2%).
Primary analyses
TRP infusion significantly modified all negative affect
ratings from baseline whereas sham infusion did not.
Table 1 provides the POMS means for each affect at
baseline, post-infusion, and the change for each POMS
rating for both sham and TRP infusion days. Next we
analyzed the effect of gender and genotype on change in
the four affect types, adjusted for baseline and race. Neither
gender nor genotype were found individually to display
significant differences on negative affects. However, the
interaction of genotype and gender was a statistically sig-
nificant predictor of change in depression-dejection
(P = .013). This interaction was a nonsignificant predictor
for fatigue-inertia, tension-anxiety, and anger-hostility,
although anger-hostility did show a trend (P = .084). The
change in depression-dejection scores by genotype and
gender are provided in Table 2 and graphically depicted in
Fig. 1. Table 3 presents the results of the regression anal-
ysis for depression-dejection scores. Males in the HiHi
genotype group had significantly greater increases in
depression-dejection ratings affect during infusion, com-
pared to all groups except LoLo genotype females. LoLo
genotype females also showed significant increases in
depression-dejection from baseline to post-infusion ratings.
None of the remaining group comparisons were significantly
different from one another. The pattern of change for
anger-hostility was similar to that of depression-dejection.
Table 1 POMS baseline and post infusion values for sham (day 1)







Anger-hostility 1.3 (0.3) 1.9 (0.5) 0.60 (0.3), 0.070
Depression-
dejection
3.4 (0.5) 3.5 (0.6) 0.12 (0.4), 0.779
Fatigue-inertia 3.4 (0.4) 3.4 (0.4) -0.01 (0.3), 0.966
Tension-anxiety 4.5 (0.4) 5.0 (0.6) 0.55 (0.5), 0.261
TRP infusion—day 2
Anger-hostility 1.5 (0.5) 2.8 (0.8) 1.3 (0.5), 0.018
Depression-
dejection
3.0 (0.6) 5.2 (1.0) 2.2 (0.7), 0.003
Fatigue-inertia 4.4 (0.3) 6.5 (0.5) 2.1 (0.5), 0.001
Tension-anxiety 3.8 (0.5) 6.1 (0.5) 2.3 (0.5), 0.001
Note: P-values are those associated with paired t-tests for baseline to
post-infusion change
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No significant differences were found in negative affects
based on gender or genotype alone.
On sham day-1 none of the product interaction terms for
genotype 9 gender, nor their main effects, were significant
predictors of any of the four negative affect change scores.
Discussion
To our knowledge this is the first study to examine both
gender and functional variation in 5-HTTLPR as predictors
of negative emotional reactions to an acute TRP infusion in
a non-clinical sample. Importantly, the current pattern of
results complements prior research that suggests for
chronically stressed males the presence of 5-HTTLPR
alleles that convey increased transcriptional activity may
be associated with increased depressive symptoms. More
broadly, the findings contribute to an existing literature
indicating that, in males as compared to females, the
serotonin system functions differently in ways that have
implications for emotional wellbeing.
Apart from inclusion of a healthy control group for
comparison purposes, emotional response to TRP infusion
in nondepressed individuals has not been a focus of prior
research. Prior to examination of moderating factors, our
initial findings in the present sample suggest that TRP
infusion results in increased negative emotion in healthy
subjects. Similarly, a study of TRP infusion that included a
healthy control group (Price et al. 1991) reported that
control subjects were less happy, talkative, and energetic
following infusion. Others have demonstrated increases in
tiredness or drowsiness following TRP infusion in healthy
controls (Cowen and Charig 1987; Heninger et al. 1984).
Finally, TRP infusion was associated with increased feel-
ings of anger, depression, tension, and fatigue in a sample
of healthy controls and nondepressed subjects with a first-
degree relative with bipolar disorder (Sobczak et al. 2003).
Thus, the present findings concur with those previously
reported in nondepressed subjects, suggesting that the acute
infusion of TRP in healthy individuals leads to a general
pattern of increased negative emotional responding.
Additionally, the current study goes a step beyond prior
research in this area by including examination of gender
and genotype.
The present results also complement findings from other
research evaluating effects of chronic stress on depressive
symptoms that suggest that 5-HTTLPR allelic variation
may have an opposite effect on depressive symptoms in
chronically stressed men and women. Specifically, in







Male HiHi (n = 15) 3.2 (1.7) 9.4 (3.0) 6.2 (2.3) 0.019
Male HiLo (n = 19) 2.7 (1.0) 4.2 (1.5) 1.5 (0.8) 0.080
Male LoLo (n = 7) 2.9 (1.7) 1.5 (0.7) -1.4 (1.8) 0.450
Female HiHi (n = 11) 5.2 (2.4) 5.6 (1.9) 0.4 (1.9) 0.849
Female HiLo (n = 11) 1.4 (0.5) 3.2 (1.3) 1.8 (1.3) 0.183
Female LoLo (n = 9) 2.8 (2.1) 5.4 (2.9) 2.6 (1.1) 0.050
Note: Mean change values are unadjusted, and P-values are those
































Pre-infusion Post-infusion Pre-infusion Post-infusion
Fig. 1 Day-2 active tryptophan
infusion: means for pre-infusion
and post-infusion ratings of
depression-dejection by
genotype and gender
Table 3 Regression analysis for POMS depression–dejection scores
following TRP infusion
Source F-value (df) P-value
Baseline depression-dejection rating 82.7 (1) 0.001
Race (African American, Caucasian) 2.6 (1) 0.111
Gender 0.1 (1) 0.723
Genotype (HiHi, HiLo, LoLo) 1.4 (2) 0.247
Gender 9 Genotype interaction term 4.7 (2) 0.013
Note: Results are from type 3 sums of squares
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chronically stressed males the presence of the L allele is
associated with negative behavioral traits such as symp-
toms of depression, whereas, in chronically stressed
females it is the S allele that is associated with increased
symptoms of depression (Brummett et al. 2008, 2003; Eley
et al. 2004; Flory et al. 1999; Gonda et al. 2005; Jacobs
et al. 2006; Sjoberg et al. 2006). The current results par-
allel these findings by showing that acutely increasing TRP
levels increases negative affect in males with 5-HTTLPR
alleles associated with the highest level of serotonin
transporter transcription, while in females TRP infusion
increased negative affect, but only for those with
5-HTTLPR alleles associated with the lowest levels of
serotonin transporter transcription. Prior research has doc-
umented that acute stress causes an increase in 5-HT
release in the CNS (Chaouloff 1993). Changes in negative
mood following the pharmacological enhancement of
extra-cellular CNS 5-HT by TRP infusion may be similar
to those changes that accompany psychological stress in
daily life. Thus, these findings suggest that the present
gender differences in 5-HTTLPR moderation of mood
responses to acute enhancement of CNS 5-HT neuro-
transmission could be analogous to a similar effect in
several chronically stressed samples. That is, higher levels
of depressed symptoms reported in chronically stressed
men with L/L genotype and in women with S/S genotype
could be caused by the accumulation of repeated effects of
acute stress to increase CNS serotonin activity, c.f. (Dunn
1998), which then engenders acute increases in depressed
mood in men with high expressing 5-HTTLPR alleles and
in women with low expressing alleles.
Currently sex differences in serotonergic function are not
well understood. Ovarian steroid modulation of serotonergic
function may play an important role in gender differences
seen in CNS serotonin function—especially those that may
influence depressive symptoms—as ovarian steroids clearly
affect serotonin synthesis, its removal from the synapse, its
metabolism and also its stimulation of pre and postsynaptic
receptor populations (Bethea et al. 2002; Gundlah et al.
2002; Lu and Bethea 2002; Pecins-Thompson and Bethea
1999; Smith et al. 2004). It seems transporter expression, as
influenced by 5-HTTLPR genotype, may also play a critical
role in the association we report here between sex and neg-
ative affective responses. In 5-HT1b knockout mice, females
exhibit greater disinhibition of serotonin release which
manifests as less depressive behavior than 5 HT1b knockout
males. These findings suggest that the presynaptic 5-HT1b
autoreceptors contribute differentially to regulation of
extracellular serotonin in intact females and intact males.
The observed changes in the present study suggest that there
is either a different balance of reuptake, synthesis, and
receptor sensitivity controlling serotonergic tone in men and
women; or that the promoter polymorphisms are not directly
controlling 5-HT expression in adulthood, but influence the
development of the serotonin system in a gender-specific
way. Gender influence on regulation of release, reuptake, and
receptor sensitivity likely coordinate in a complex way to
control extracellular serotonin in men and women; thus the
critical test would include a valid measure of extracellular
serotonin.
Certain limitations should be noted with respect to the
present findings. The sample in this experiment consisted
of only 72 participants, thus all results should be inter-
preted with proper caution. Replication in additional
samples will be required in order to determine their
validity. The lack of a stronger relation in the opposite
direction for females may have been due to lack of ade-
quate power, which is a particularly important issue to be
considered when examining models that contain interac-
tions. In addition, we were unable to examine ethnicity as a
further moderator due to insufficient numbers of partici-
pants in certain cells.
The present findings contribute to a large body of prior
work indicating that the CNS serotonin system behaves
differently in men and women in many important ways
(Biver et al. 1996; Costes et al. 2005; Jonsson et al. 2000;
Kornstein et al. 2000; Nishizawa et al. 1997; Williams et al.
2003). More specifically, the current results corroborate
recent findings indicating that the presence of the more high
expressing allele of the 5-HTTLPR polymorphism may
place chronically stressed males at higher risk for depressive
symptoms. They also suggest a mechanism whereby acute
increases in depressive mood engendered by stress-induced
acute increases in CNS 5-HT activity may, over time, lead to
increased sustained depressive symptom levels in males with
the more high expressing alleles, with a similar mechanism
accounting for high depressive mood levels in chronically
stressed women with low expressing alleles. It is likely that
continued converging results from related areas of research
that use both experimental and epidemiological approaches
will provide insight into the ways in which sex differences in
serotonergic functioning impact emotional, as well as
physical health, for both men and women.
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